Clinical Trial Detail

NCT ID NCT02950766
Title A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Patrick Ott, MD
Indications

renal cell carcinoma

Therapies

Ipilimumab + NeoVax

Age Groups: senior adult

No variant requirements are available.